Mizuho Securities has adjusted its price target for Glaukos Corporation (GKOS, Financial), bringing it down to $175 from the previous $200. Despite this reduction, the firm maintains an Outperform rating on the company's shares. This adjustment comes as part of Mizuho's first-quarter preview within the medical devices and diagnostics sector.
The decision to lower the price target reflects several critical factors influencing Glaukos's upcoming quarterly performance. Mizuho cites potential impacts from tariffs, the company's exposure to the Chinese market, and recent trends in medical procedure outlooks as significant considerations. Due to these elements, the firm has opted to revise its figures ahead of the official first-quarter results.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Glaukos Corp (GKOS, Financial) is $156.23 with a high estimate of $200.00 and a low estimate of $110.00. The average target implies an upside of 65.29% from the current price of $94.52. More detailed estimate data can be found on the Glaukos Corp (GKOS) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Glaukos Corp's (GKOS, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Glaukos Corp (GKOS, Financial) in one year is $104.96, suggesting a upside of 11.05% from the current price of $94.52. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Glaukos Corp (GKOS) Summary page.
